Mebex

Quick links to important sections

Mebex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mebex

Property Description
Active ingredient Mebendazole
Form Tablets, Oral Suspension
Pharmacological class Anthelmintic
Common Use Clearance of parasitic worms
Origin Synthetic compound

What Type of Medicine is Mebex (Mebendazole)?

Mebex is a pharmaceutical product primarily containing the active substance Mebendazole (INN). It is systematically classified as an anthelmintic, a specific category of medicine developed to counter internal parasitic worm infestations. Mebendazole is a synthetic compound that belongs to the chemical umbrella of Benzimidazole derivatives. The Benzimidazole class is recognized for its application across a range of gastrointestinal parasites. The medication is designated for oral administration, ensuring it is delivered directly to the gastrointestinal tract.


Composition and Available Oral Forms

The core composition of Mebex relies on a single active agent, Mebendazole, combined with pharmaceutical excipients that facilitate proper delivery. Mebendazole is commonly manufactured in several oral dosage forms, including standard tablets, chewable tablets, and a liquid oral suspension. The availability of both solid and liquid forms provides flexibility for administration across different patient groups. Furthermore, Mebendazole is widely categorized as an essential medicine, reflecting its role in basic healthcare systems.


How Mebendazole Generally Targets Parasites

Mebendazole works by initiating a targeted nutritional disruption within the parasitic organisms, leading to their starvation. The compound selectively interferes with the worms' ability to uptake and utilize glucose, a vital nutrient source required for their energy and survival. This action results in the rapid depletion of the parasites' energy reserves, leading to their immobilization and eventual death. The essential benefit of this focused action is the non-invasive, systemic clearance of the parasitic load from the body, contributing to the restoration of normal digestive function.

Regulatory References

  1. Mebendazole: MedlinePlus Drug Information

What side effects are possible with Mebex?

The officially documented safety profile for Mebendazole (Mebex) organizes potential adverse effects based on frequency and the body system affected, as classified by government regulatory authorities.

Frequency-Classified Adverse Reactions

The majority of reported adverse reactions are associated with the gastrointestinal tract:

  • Common: Abdominal pain and Diarrhea are the most frequently documented adverse reactions, often presenting transiently.
  • Uncommon: Adverse effects such as Headache and Dizziness have been reported in regulatory documents.
  • Rare: Reactions classified as rare include Rash, Urticaria (hives), and reversible Alopecia (hair loss).

Serious Adverse Reactions and Safety Notes

The safety profile includes rare but serious adverse reactions, primarily reported during post-marketing surveillance, which impact specific organ systems:

  • Blood and Liver: Rare cases of severe blood disorders, including Neutropenia and Agranulocytosis, and Hepatitis (liver inflammation) have been documented. These are predominantly associated with use at higher doses or for prolonged durations that exceed standard recommendations.
  • Skin: Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are extremely rare but officially listed.

Special Safety Considerations:

Regulatory documents note that the co-administration of Mebendazole with Metronidazole has been associated with an increased risk of severe skin reactions (SJS/TEN) and should generally be avoided. Additionally, the safety and efficacy of the medication are not established for use in children younger than two years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information defines the risks and management procedures for Mebex (mebendazole) overdose. This information is critical for recognizing a possible overdose and initiating the correct emergency response.

Documented Overdose Presentations

An acute accidental overdose may primarily result in transient, self-limiting gastrointestinal distress. The documented manifestations are:

  • Abdominal cramps
  • Nausea
  • Vomiting
  • Diarrhea

Overdose Severity and High-Dose Exposure

While acute overdose usually involves only gastrointestinal symptoms, more serious systemic effects have been reported rarely in patients who received dosages substantially higher than recommended or received treatment for prolonged periods of time. These rare, delayed outcomes can involve disturbances to the liver (hepatitis, reversible liver function changes) and blood-forming systems (agranulocytosis, neutropenia), as well as hair loss (alopecia) and kidney issues (glomerulonephritis).

Immediate Actions and Emergency Care

When to Seek Help: If an overdose of Mebex is suspected, you must contact emergency medical services or a Poison Control Centre immediately, even if no symptoms are currently present.

Treatment: There is no specific pharmacological antidote to reverse the effects of mebendazole. Treatment is focused on supportive and symptomatic care to stabilize the patient. Medically supervised administration of activated charcoal may be considered to help prevent further absorption of the drug from the stomach.

Therapeutic Uses of Mebex

What Mebex treats: main uses and benefits

Mebex (Mebendazole) is used in contexts involving a heightened systemic burden related to intestinal parasitic worms, known clinically as helminthiasis. This therapeutic use is applied in situations where support is needed to address the source of infection and helps support general well-being during symptomatic phases.

The medication primarily helps manage infections caused by pinworm (Enterobius), roundworm (Ascaris), whipworm (Trichuris), and hookworm (Necator or Ancylostoma). It is often applied in cases involving mixed infections where broad-spectrum support is required.

When applied to address these conditions, the treatment may assist with maintaining functional stability within the gastrointestinal tract and contributes to easing the overall symptom load.

The medication helps manage symptoms related to physical discomfort, including pronounced abdominal pain, fluctuating symptomatic patterns, and symptoms related to systemic imbalance, such as loss of appetite. It is also used for easing the symptomatic pattern of nocturnal perianal itching (pruritus), which often interferes with daily functioning—especially in children—as the treatment supports the patient during difficult episodes by easing distress.


Quick Fact: Relief for Pruritus and Intestinal Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Mebex (mebendazole) is subject to specific regulatory eligibility rules and contraindications documented by government health authorities worldwide.

Contraindicated Populations

  • Hypersensitivity: Individuals with a known allergy to mebendazole or its excipients must not use this medicine.
  • Children under 1 year of age: Use is contraindicated due to insufficient safety data and post-marketing reports of convulsions in this age group.
  • Concomitant Use with Metronidazole: Co-administration must be avoided due to the documented risk of serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).

Restricted or Conditional Use

  • Pregnancy and Lactation: Use during pregnancy is not generally recommended or is contraindicated by some authorities, particularly in the first trimester, based on animal data showing embryotoxicity. It is unknown if mebendazole is excreted in human milk, thus caution is advised for breastfeeding women.
  • Children 1 to 2 years of age: Safety and effectiveness have not been extensively established across all formulations, and its use requires careful consideration of potential benefit versus risk.
  • Comorbidities: Caution and periodic monitoring of blood counts and liver function are required for patients with pre-existing liver disease or those receiving higher doses or prolonged therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interactions for mebendazole (Mebex) based on regulatory information.


Contraindicated Combinations

Metronidazole: Concomitant use of mebendazole and metronidazole should be avoided. Post-marketing reports have indicated an association between the co-administration of these two medicines and the occurrence of serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).

Clinically Significant Pharmacokinetic Interactions

Regulatory documents identify substances that affect the concentration of mebendazole in the body, which is primarily metabolized in the liver.

Interaction Type Interacting Medicines Resulting Effect on Mebendazole
Increased Exposure Cimetidine Increases mebendazole plasma concentrations by inhibiting its metabolism.
Decreased Exposure Phenytoin, Carbamazepine, Fosphenytoin, Ritonavir May lower mebendazole plasma concentrations due to enzyme induction, potentially reducing effectiveness.

Food and Population Considerations

Food: Mebendazole absorption is enhanced when the medicine is taken with food, particularly a high-fat meal, which increases systemic exposure.

Impaired Hepatic Function: Patients with significantly reduced liver function may experience higher plasma levels of mebendazole and a prolonged half-life due to altered metabolism.

Mechanism of Action

Mebex's Mechanism of Action (Pharmacodynamics)

Mebex (mebendazole) acts primarily through the selective inhibition of microtubule polymerization in susceptible parasitic helminth cells. The drug functions as a binding agent to beta-tubulin dimers at the colchicine-sensitive site, specifically disrupting the parasite's cytoplasmic microtubular structure . This molecular interaction initiates a cascade that impairs critical intracellular functions.

The resulting structural failure directly blocks the parasite's glucose uptake and subsequent metabolism, leading to a rapid depletion of ATP and glycogen stores. This metabolic collapse causes functional failure and eventual non-viability of the parasite.

Crucially, Mebex exhibits low systemic bioavailability in the host, resulting in a restricted peripheral action. The mechanism is thus concentrated in the gastrointestinal lumen, ensuring selective engagement with the parasite's cellular systems.

Dosage and Administration Information

How to use Mebex

Mebendazole is administered exclusively by the oral route, available in dosage forms including tablets, chewable tablets, and a liquid oral suspension. The protocol for use is strictly determined by the specific parasitic infection being addressed, adhering to regulatory specifications. For pinworm infection (Enterobiasis), the standard usage pattern is a single oral dose of 100 mg.

For the treatment of whipworm, roundworm, and hookworm, the labeled regimen is 100 mg taken twice daily, morning and evening, for three consecutive days. Furthermore, in contexts involving mass drug administration, a 500 mg single dose is specified for patients one year of age and older.

The administration is flexible and not dependent on meal timing; the medicine may be taken with or without food. A key instruction is the flexibility afforded by the tablet forms: the medicine can be chewed, swallowed whole, or crushed and mixed with food to facilitate proper intake. No special pre-administration procedures, such as fasting or purging, are required. Dosing recommendations for the 100 mg schedule apply equally to adults and pediatric patients aged 2 years and older. Treatment cycles are often short-term, but regulatory instructions specify that a second, identical course of treatment may be utilized after a three-week interval if the initial course does not achieve the intended clearance.

Recent Clinical Evidence

Research evidence / Overview of Studies for Mebex


Evidence for Use in Roundworm and Pinworm Infections

Research primarily focused on the clinical evaluation of treatment for parasitic infections, with extensive data coming from studies of Roundworm (Ascaris lumbricoides) and Pinworm (Enterobius vermicularis). These indications have been studied using large-scale Randomized Controlled Trials (RCTs) and Systematic Reviews. Researchers examined the effects of treatment by measuring key study findings like the Parasite Absence Rate (PAR), defined as the absence of parasite eggs or ova in samples taken after treatment, and the Egg Reduction Rate (ERR), which measures the decrease in the number of eggs found.

Findings from these trials reported high measurements of the measured study findings associated with the short-term administration schedule. For roundworm specifically, studies documented high measurements of the measured study findings associated with single-dose administration in the evaluated populations. Similarly, pinworm trials, which often involve treating entire households due to the contagious nature of the infection, documented high measurements of the Absence of Ova Rate (AOR) in the observed populations.


Evidence for Whipworm and Hookworm Infections

The research base for Whipworm (Trichuris trichiura) and Hookworm (Necator americanus / Ancylostoma duodenale) also involves numerous RCTs and Systematic Reviews, but the findings describe more variable patterns of the measured study findings. For both whipworm and hookworm, studies described measured Parasite Absence Rates following single-dose administration that described lower measurements than those documented for other parasitic conditions.

Research explored multi-day regimens (e.g., three consecutive days of administration) and reported that higher measured study findings were associated with these regimens compared to a single dose. Findings for hookworm were mixed, and some reviews described a pattern of declining reported efficacy measurements in research over time, suggesting the evidence quality varies across studies.


Areas of Research Uncertainty and Study Limitations

The evidence landscape, while extensive, presents several areas where the consistency of findings remains low and further research is ongoing. One key limitation is the variability of findings reported for hookworm and whipworm, particularly with single-dose regimens, where findings were mixed across different studies and geographic regions. Additionally, the research is largely focused on the short-term measured study findings, meaning that long-term data regarding re-infection rates are not fully established.

Key Studies & References

  1. Efficacy of Current Drugs Against Soil-Transmitted Helminth Infections (Systematic Review and Meta-Analyses)
  2. Assessment of Anthelmintic Efficacy of Mebendazole in School Children in Six Countries Where Soil-Transmitted Helminths Are Endemic
  3. Mebendazole - LiverTox - NIH National Library of Medicine (for safety/contextual use)

Frequently Asked Questions (FAQ)

Common questions about Mebex (FAQ)


Q: Do I need a prescription to get Mebex?

In the United States and many other global regions, the active substance in Mebex, mebendazole, is generally classified as a prescription-only medicine. Regulatory information indicates that it is available to patients only through a healthcare professional's authorization. Official sources define its use as administered under strict adherence to regulatory specifications for parasitic infections.


Q: What happens if I stop using Mebex too soon?

Regulatory guidance suggests that completing the full prescribed course is associated with achieving the intended clearance. Regulatory instructions state that if the initial course does not achieve the intended clearance, a second, identical course of treatment may be utilized. This follow-up is specified to occur after a three-week interval, based on the specific regulatory protocol for the type of infection.


Q: Is it okay to drive or operate machinery after using Mebex?

Official product information documents indicate that Mebex may cause side effects such as dizziness. Patients who experience this central nervous system (CNS) effect are generally advised to use caution. If this or any other adverse reaction is experienced, patients are advised to consult their health professional regarding the safety of performing activities like driving or operating machinery.


Q: Are there any known issues with taking Mebex and alcohol?

Official regulatory health information and core monographs do not typically document specific known issues or warnings regarding the use of alcohol while taking mebendazole. It is generally acknowledged that all medicines carry a potential for interaction with various substances.


Q: What should I do if a side effect seems mild but bothersome?

Official patient counseling materials indicate that contacting a healthcare provider is appropriate for any adverse reaction that is bothersome or does not resolve. This professional consultation facilitates the proper assessment and management of the reaction according to established health guidelines.


Q: Is it normal to feel a change in appetite while using Mebex?

Official clinical trial and postmarketing reports have documented a loss of appetite, also known as anorexia, as a potential adverse reaction. This reaction has been reported in observed populations. Any unexpected changes in appetite are typically recommended to be discussed with a healthcare professional.


Q: What are the safety classifications for Mebex (e.g., FDA pregnancy category)?

Regulatory safety systems provide classifications to describe potential risk during specific periods, such as pregnancy. The TGA (Australia) classification for mebendazole is B3. While the US FDA has been transitioning away from the letter-based system, mebendazole was historically assigned Category C.


Q: How long does Mebex stay in your system?

Mebendazole is characterized by low systemic bioavailability, which means very little of the drug is absorbed into the bloodstream. The majority of the dose is excreted in the feces. The reported half-life for the small amount that does enter the bloodstream is typically short, ranging from three to nine hours.


Q: Can Mebex be used for purposes other than what is listed on the label?

Official product labeling and regulatory information strictly address the medicine's approved uses for specific parasitic infections. The discussion or recommendation for using any medicine for indications that are not explicitly approved by regulatory authorities is not included in official patient labeling.


Q: What is the difference between Mebex and [a common similar drug]?

The brand name Mebex contains the active ingredient mebendazole. While different brand names or generic versions may contain this same active component, they may vary in their specific strength, inactive ingredients, or overall formulation. Official sources confirm the active ingredient's chemical identity.


Q: Is Mebex known to interact with common pain relievers like paracetamol or ibuprofen?

The core regulatory interaction lists focus on medicines that significantly impact mebendazole's metabolism, such as cimetidine and certain anti-convulsants. No specific warnings or drug-to-drug interactions are currently listed in official documents for co-administration with common pain relievers like paracetamol or ibuprofen.


Q: Does Mebex make you feel tired or drowsy?

Post-marketing and incidence-not-known reports have included central nervous system effects such as drowsiness and a general feeling of weakness or being tired. This type of effect is not classified as common but has been reported in observed populations.


Q: Is Mebex suitable for elderly patients?

Clinical trials and official safety evaluations for mebendazole generally include adult and pediatric subjects. Some approved labeling does not specify an upper age restriction for use. However, regulatory documents indicate that special considerations, such as monitoring liver function, may apply to patients with pre-existing conditions.


Q: Can Mebex interact with any herbal supplements?

Regulatory patient counseling consistently includes a statement that patients should ensure their healthcare professional is aware of all products being used. This includes prescription and nonprescription medicines, vitamins, and herbal supplements. This precaution is advised due to the potential for unknown or undocumented interactions.


Q: Does using Mebex affect birth control pills?

Official interaction lists prioritize medicines that significantly alter the amount of mebendazole in the body, such as Metronidazole and Cimetidine. Core regulatory documents do not list a specific interaction between mebendazole and oral contraceptives.


Q: Is Mebex known to interact with blood thinning medications?

Regulatory interaction lists focus on medicines that affect metabolism, such as anti-convulsants. No specific warnings or interactions are currently listed in official documents for co-administration with common blood thinning medications like warfarin.


Q: Can Mebex cause changes to sleep patterns?

While specific changes to sleep patterns, such as insomnia, are not frequently listed, post-marketing reports have included central nervous system effects like drowsiness. These effects have been observed in some patients and are a type of documented nervous system adverse reaction.


Q: Does Mebex affect blood sugar levels?

The medicine's known mechanism of action focuses on blocking the parasite's glucose uptake. However, some independent research has explored its influence on insulin secretion and plasma glucose concentration in diabetic patients. This finding is typically not listed as a standard clinical interaction on most official regulatory labels.

How should Mebex be stored and disposed of?

How to Store and Dispose of Mebex?

Storage Requirements

Mebex (Mebendazole) must be stored at Controlled Room Temperature, which is between 68 and 77 F (20 and 25 C). It is essential to keep the medication in the container it came in, with the cap tightly closed, to protect it from freezing, excess heat, moisture, and direct light. The bottle or container must be kept up and away, completely out of the sight and reach of children, in compliance with safety regulations.

Disposal Instructions

To dispose of unused or expired Mebex, follow any instructions provided on the drug's label. The recommended method is to use a drug take-back program. If a program is not available, mix the medication with an undesirable substance, such as dirt or used coffee grounds. Place the mixture in a sealed bag or container before discarding it in the household trash. Do not flush Mebex down the toilet unless specifically instructed to do so by an authorized source.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mebex found in:

A-Z Index: